SEO URLwww.firestrike.ai/deals/cidara-therapeutics-merck-sharp-dohme-llc-acquisition-2026
acquisitionAnnounced · Jan 7, 2026Professional, Scientific, and Technical Services (541)Source · CredibleArticle · Factual
Merck Sharp & Dohme LLC acquires Cidara Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$7B
Target
Cidara Therapeutics
NASDAQ: CDTX · San Diego, California
Acquirer
Merck Sharp & Dohme LLC
Full Acquisition
Status
Completed
Merck Sharp & Dohme LLC agreed to acquire Cidara Therapeutics. Reported deal value: $7B. Status: Completed. Sector: Not specified. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.
Merck Sharp & Dohme LLC entered into an Agreement and Plan of Merger to acquire Cidara Therapeutics , Inc. for $7 billion on November 13, 2025
Deal timeline
Announced
Jan 7, 2026 · marketscreener.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Professional, Scientific, and Technical Services (541) with a reported deal value of $7B. Figures and status may change as sources update.
Sources: marketscreener.com · Primary article · FireStrike proprietary index